An Unseen Cost of the Ukraine War
Cromos Pharma’s CEO Vlad Bogin was interviewed by Spotlight on America as part of its investigative report on the situation with clinical trials in Ukraine.
Not long-ago Ukraine was a highly attractive location for clinical trials offering numerous distinct advantages for international sponsors including:
- Excellent recruitment potential due to its large population of modern treatment-naïve patients
- Full alignment with EU standards and directives in relation to clinical trials
- A well-organized centralized health system
- Large pool of highly skilled and motivated medical professionals fully compliant with ICH GCP standards
However research in Ukraine has become nearly impossible due to the war, which has already resulted in 200 attacks on medical facilities. The medical infrastructure of Ukraine is being destroyed, which means that potentially life-saving research is being disrupted.
Vlad Bogin was interviewed among other colleagues, Dr. Julie Gralow, the Chief Medical Officer of the American Society of Clinical Oncology, and Ariel Katz, CEO of H1. Each of them claims that the potential that has been developed over the years to conduct successful research in Ukraine has been nearly completely disrupted by the military action.
Cromos Pharma had 12 ongoing clinical trials in Ukraine at the time the war broke out.
“There was a shock, it was completely unexpected,” said Vlad Bogin. “Clearly our initial thoughts were about the people that were in Ukraine, our staff, and we tried to make sure they were safe.”
Since the top priority in any clinical trial conducted by Cromos Pharma is patient safety, the main task of the company’s employees was to track down patients who had fled due to hostilities and help them relocate to a safe place to continue life-saving treatments. One of the most successful operations for Cromos Pharma was tracking down of 58 out of 60 patients participating in a rare cancer trial and allowing them to continue treatment.
The future of clinical trials in Ukraine remains unknown, but Cromos Pharma and its partners do everything possible to ensure the safety of the patients and staff during these hard times.
Please read the story and watch the video here.
Cromos Pharma in Ukraine
Cromos Pharma has been conducting clinical trials in Ukraine since 2006 and established its representative office in Kyiv in 2008. Since then, our highly experienced team in Ukraine has consistently delivered exceptional results for international sponsors.
About Cromos Pharma
Cromos Pharma provides tailored and effective clinical trial services to support the development of drugs that transform healthcare. As a US-based international CRO, with over 18 years’ experience, it offers fully integrated services in all aspects of clinical trials in all clinical phases across a wide range of therapeutic areas. Cromos Pharma delivers rapid recruitment and excellent patient retention as well as expert study design and management. Cromos Pharma has strong regional experience in Central and Eastern Europe. Its US HQ is in Portland, Oregon and its European HQ is situated in Dublin, Ireland.